These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15178952)

  • 1. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia.
    Hampel H; Teipel SJ
    Dement Geriatr Cogn Disord; 2004; 17(4):350-4. PubMed ID: 15178952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.
    Riemenschneider M; Wagenpfeil S; Vanderstichele H; Otto M; Wiltfang J; Kretzschmar H; Vanmechelen E; Förstl H; Kurz A
    Mol Psychiatry; 2003 Mar; 8(3):343-7. PubMed ID: 12660807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.
    Engelborghs S; De Vreese K; Van de Casteele T; Vanderstichele H; Van Everbroeck B; Cras P; Martin JJ; Vanmechelen E; De Deyn PP
    Neurobiol Aging; 2008 Aug; 29(8):1143-59. PubMed ID: 17428581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations.
    Rosso SM; van Herpen E; Pijnenburg YA; Schoonenboom NS; Scheltens P; Heutink P; van Swieten JC
    Arch Neurol; 2003 Sep; 60(9):1209-13. PubMed ID: 12975285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia.
    Gabelle A; Roche S; Gény C; Bennys K; Labauge P; Tholance Y; Quadrio I; Tiers L; Gor B; Boulanghien J; Chaulet C; Vighetto A; Croisile B; Krolak-Salmon P; Perret-Liaudet A; Touchon J; Lehmann S
    J Alzheimers Dis; 2011; 26(3):553-63. PubMed ID: 21709372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Added diagnostic value of CSF biomarkers in differential dementia diagnosis.
    Le Bastard N; Martin JJ; Vanmechelen E; Vanderstichele H; De Deyn PP; Engelborghs S
    Neurobiol Aging; 2010 Nov; 31(11):1867-76. PubMed ID: 19150153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
    Formichi P; Battisti C; Radi E; Federico A
    J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
    Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
    J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias.
    Blasko I; Lederer W; Oberbauer H; Walch T; Kemmler G; Hinterhuber H; Marksteiner J; Humpel C
    Dement Geriatr Cogn Disord; 2006; 21(1):9-15. PubMed ID: 16244482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
    J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid levels of a 20-22 kDa NH2 fragment of human tau provide a novel neuronal injury biomarker in Alzheimer's disease and other dementias.
    Amadoro G; Corsetti V; Sancesario GM; Lubrano A; Melchiorri G; Bernardini S; Calissano P; Sancesario G
    J Alzheimers Dis; 2014; 42(1):211-26. PubMed ID: 24851856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease].
    Hu Y; He S; Wang J
    Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1377-9. PubMed ID: 11930632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF phosphorylated tau--does it constitute an accurate biological test for Alzheimer's disease?
    Mitchell A; Brindle N
    Int J Geriatr Psychiatry; 2003 May; 18(5):407-11. PubMed ID: 12766916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
    Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychological and behavioural correlates of CSF biomarkers in dementia.
    Engelborghs S; Maertens K; Vloeberghs E; Aerts T; Somers N; Mariën P; De Deyn PP
    Neurochem Int; 2006 Mar; 48(4):286-95. PubMed ID: 16434124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.
    Boban M; Grbić K; Mladinov M; Hof PR; Süssmair C; Ackl N; Stanić G; Bader B; Danek A; Simić G
    Coll Antropol; 2008 Jan; 32 Suppl 1():31-6. PubMed ID: 18405055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.